PD-L1 Mouse mAb [C36S]

Cat NO. : A90017

Information:

Applications	Reactivity:	UniProt ID:	MW(kDa)	Host	Isotype	Size
WB	н	Q9NZQ7	40-50 kDa	Mouse	lgG	100ul,200ul

Applications detail:

Application Dilution WB 1:1000-2000 The optimal dilutions should be determined by the end user

Conjugate:

UnConjugate

Form:

Liquid

sensitivity:

Endogenous

Purification:

Protein A purification

Specificity:

Antibody is produced by immunizing animals with a synthetic peptide at the sequence of Human PD-L1

Storage buffer and conditions:

Antibody store in 10 mM PBS, 0.5mg/ml BSA, 50% glycerol (buffer) .

Shipped at 4°C. Store at-20°C or -80°C.

Products are valid for one natural year of receipt. Avoid repeated freeze / thaw cycles.

Tissue specificity:

Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and

Subcellular location:

Cell membrane,Single-pass type I membrane protein. Early endosome membrane,Single-pass type I membrane protein. Recycling endosome membrane,Single-pass type I membrane protein.

Introduction: WB: Western Blot IP: Immunoprecipitation IHC: Immunohistochemistry ChIP: Chromatin Immunoprecipitation ICC/IF: Immunocytochemistry/ Immunofluorescence F: Flow Cvtometry


Cross Reactivity: H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus MI: mink C: chicken Dm D. melanogaster X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Hr: horse

For Research Use Only. Not For Use In Diagnostic Procedures.

Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813417, PubMed:28813410). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813417, PubMed:28813410). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077)..., The PDCD1-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and escape destruction by the immune system, thereby facilitating tumor survival (PubMed:28813417, PubMed:28813410). The interaction with PDCD1/PD-1 inhibits cytotoxic T lymphocytes (CTLs) effector function (By similarity). The blockage of the PDCD1-mediated pathway results in the reversal of the exhausted T-cell phenotype and the normalization of the anti-tumor response, providing a rationale for cancer immunotherapy (By similarity).

Validation Data:

PD-L1 Mouse mAb [C36S] Images



Western blot (SDS PAGE) analysis of extracts from KARPAS-299 cells.Using PD-L1 mouse mAb[C36S] at dilution of 1:1000 incubated at 4°C over night.

View more information on http://naturebios.com

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 1% w/v Milk, 1X TBST at 4°C overnight.